Anna Algamas-Dimantov1, Einav Yehuda-Shnaidman, Irena Peri, Betty Schwartz. 1. Institute of Biochemistry, Food Science and Nutrition, The Robert H. Smith Faculty of Agriculture, Food and Environment, The Hebrew University of Jerusalem, P.O. Box 12, Rehovot, 76100, Israel.
Abstract
BACKGROUND: We previously found that enhanced expression of hepatocyte nuclear factor 4α (HNF-4α) is associated with hyper-proliferation of colon carcinoma cells. Here, the effect of histone deacetylase (HDAC) inhibitors on proliferation and the expression of HNF-4α and its downstream target genes were assessed in HM7, LS174T, HT29 and Caco-2 colon carcinoma cell lines. RESULTS: HNF-4α expression was found to vary in the different colon carcinoma cell lines tested, being highest in HM7. Additionally, a direct correlation with proliferation was observed. In HM7 cells, the weak HDAC inhibitor butyrate significantly inhibited the transcription of HNF-4α, its downstream target gene MUC4, and genes associated with proliferation, including the proliferating cell nuclear antigen gene PCNA. siRNA-mediated silencing of HNF-4α exerted an effect similar to butyrate on HM7 cell proliferation. The stronger HDAC inhibitor trichostatin A (TSA) exerted an effect similar to that of siRNA-mediated HNF-4α silencing and, concomitantly, inhibited the expression of the transcription factor gene SP1. Also, siRNA-mediated silencing of HDAC3 and HDAC4 reduced HNF-4α expression. Chromatin immunoprecipitation (ChIP) assays revealed that TSA induces hyperacetylation of histones H3 and H4 and, concomitantly, inhibits SP1 binding to the HNF-4α promoter. Subsequent electromobility shift assays supported these latter findings. CONCLUSIONS: HNF-4α transcriptional expression and activity are tightly controlled by epigenetic mechanisms. HDAC inhibitor targeting of HNF-4α may serve as an effective treatment for advanced colon carcinomas, since downstream cancer-associated target genes such as MUC4 are significantly down-regulated by this treatment.
BACKGROUND: We previously found that enhanced expression of hepatocyte nuclear factor 4α (HNF-4α) is associated with hyper-proliferation of colon carcinoma cells. Here, the effect of histone deacetylase (HDAC) inhibitors on proliferation and the expression of HNF-4α and its downstream target genes were assessed in HM7, LS174T, HT29 and Caco-2 colon carcinoma cell lines. RESULTS: HNF-4α expression was found to vary in the different colon carcinoma cell lines tested, being highest in HM7. Additionally, a direct correlation with proliferation was observed. In HM7 cells, the weak HDAC inhibitor butyrate significantly inhibited the transcription of HNF-4α, its downstream target gene MUC4, and genes associated with proliferation, including the proliferating cell nuclear antigen gene PCNA. siRNA-mediated silencing of HNF-4α exerted an effect similar to butyrate on HM7 cell proliferation. The stronger HDAC inhibitor trichostatin A (TSA) exerted an effect similar to that of siRNA-mediated HNF-4α silencing and, concomitantly, inhibited the expression of the transcription factor gene SP1. Also, siRNA-mediated silencing of HDAC3 and HDAC4 reduced HNF-4α expression. Chromatin immunoprecipitation (ChIP) assays revealed that TSA induces hyperacetylation of histones H3 and H4 and, concomitantly, inhibits SP1 binding to the HNF-4α promoter. Subsequent electromobility shift assays supported these latter findings. CONCLUSIONS: HNF-4α transcriptional expression and activity are tightly controlled by epigenetic mechanisms. HDAC inhibitor targeting of HNF-4α may serve as an effective treatment for advanced colon carcinomas, since downstream cancer-associated target genes such as MUC4 are significantly down-regulated by this treatment.
Authors: Jacinta Serpa; Francisco Caiado; Tânia Carvalho; Cheila Torre; Luís G Gonçalves; Cristina Casalou; Pedro Lamosa; Margarida Rodrigues; Zhenping Zhu; Eric W F Lam; Sérgio Dias Journal: J Biol Chem Date: 2010-10-06 Impact factor: 5.157
Authors: Scott Paterson; Kok L Sin; Jacky M Tiang; Rodney F Minchin; Neville J Butcher Journal: Drug Metab Dispos Date: 2010-09-24 Impact factor: 3.922
Authors: Betty Schwartz; Anna Algamas-Dimantov; Rachel Hertz; Jennifer Nataf; Ayelet Kerman; Irena Peri; Jacob Bar-Tana Journal: Int J Cancer Date: 2009-03-01 Impact factor: 7.396
Authors: T Tanaka; S Jiang; H Hotta; K Takano; H Iwanari; K Sumi; K Daigo; R Ohashi; M Sugai; C Ikegame; H Umezu; Y Hirayama; Y Midorikawa; Y Hippo; A Watanabe; Y Uchiyama; G Hasegawa; Pc Reid; H Aburatani; T Hamakubo; J Sakai; M Naito; T Kodama Journal: J Pathol Date: 2006-04 Impact factor: 7.996
Authors: R S Bresalier; Y Niv; J C Byrd; Q Y Duh; N W Toribara; R W Rockwell; R Dahiya; Y S Kim Journal: J Clin Invest Date: 1991-03 Impact factor: 14.808
Authors: Jolien S de Groot; Xiaojuan Pan; Jan Meeldijk; Elsken van der Wall; Paul J van Diest; Cathy B Moelans Journal: Cell Oncol (Dordr) Date: 2014-08-16 Impact factor: 6.730